Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + enzastaurin
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Bevacizumab + enzastaurin is an investigational combination therapy consisting of two agents with distinct mechanisms of action. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing tumor blood supply. Enzastaurin (LY317615) is an oral small molecule inhibitor targeting protein kinase C beta (PKCβ) and also affects the phosphoinositide 3-kinase/AKT pathway, leading to inhibition of tumor cell proliferation and survival. The rationale for combining these drugs stems from preclinical evidence suggesting synergistic antitumor effects by simultaneously inhibiting angiogenesis and key intracellular signaling pathways involved in cancer progression. This combination has been studied in phase I and II clinical trials, primarily in recurrent malignant gliomas, ovarian cancer, and other advanced cancers[1][2][3].
- Brand names
- None known for the combination
- Other names
- None known for the combination
02
Targets
PRKCB (Protein kinase C beta)GSK3 (Glycogen synthase kinase 3 beta)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + enzastaurin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + enzastaurin.